期刊
CANCER RESEARCH
卷 73, 期 11, 页码 3248-3261出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-1578
关键词
-
类别
资金
- Department of Defense Breast Cancer Research Program [BC087658, W81XWH-06-1-0325, BC083057]
- Flight Attendant Medical Research Institute
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- V Foundation
- Maryland Cigarette Restitution Fund
- Avon Foundation
- NIH [CA088843, CA009071]
- Susan G. Komen for the Cure [PDF0707944, KG090199, BCTR0707684]
- Grants-in-Aid for Scientific Research [25460395, 25640107] Funding Source: KAKEN
The selective pressures leading to cancers with mutations in both KRAS and PIK3CA are unclear. Here, we show that somatic cell knockin of both KRAS G12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in vitro, and leads to tumor formation in immunocompromised mice. Xenografts from double-knockin cells retain single copies of mutant KRAS and PIK3CA, suggesting that tumor formation does not require increased copy number of either oncogene, and these results were also observed in human colorectal cancer specimens. Mechanistically, the cooperativity between mutant KRAS and PIK3CA is mediated in part by Ras/ p110 alpha binding, as inactivating point mutations within the Ras-binding domain of PIK3CA significantly abates pathway signaling. In addition, Pdk1 activation of the downstream effector p90RSK is also increased by the combined presence of mutant KRAS and PIK3CA. These results provide new insights into mutant KRAS function and its role in carcinogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据